American Association for Cancer Research
Browse

Supplementary Table 1 from Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1–Mediated Cell Death in Uterine Cancer

Download (200 kB)
dataset
posted on 2023-04-03, 18:20 authored by Yunfei Wen, Ying Wang, Anca Chelariu-Raicu, Elaine Stur, Yuan Liu, Sara Corvigno, Faith Bartsch, Lauren Redfern, Behrouz Zand, Yu Kang, Jinsong Liu, Keith Baggerly, Anil K. Sood

Supplementary Table 1. Dataset for the reverse-phase protein array (RPPA) and processed data for Ingenuity Pathway Analysis.

Funding

Department of Defense Ovarian Cancer Research Program

NIH

Deutsche Forschungsgemeinschaft

OCRA

Donald Payne and Michael Redman

History

ARTICLE ABSTRACT

Abnormal activity of human prolactin (PRL) and its membrane-associated receptor (PRLR) contributes to the progression of uterine carcinoma. However, the underlying mechanisms are not well understood, and current means of targeting the PRL/PRLR axis in uterine cancer are limited. Our integrated analyses using The Cancer Genome Atlas and Genotype-Tissue Expression (GTEx) databases demonstrated that a short form of PRLR (PRLR_SF) is the isoform predominantly expressed in human uterine cancers; expression of this PRLR_SF was elevated in uterine cancers in comparison with cancer-free uterine tissues. We hypothesized that the overexpression of PRLR_SF in uterine cancer cells contributes, in part, to the oncogenic activity of the PRL/PRLR axis. Next, we employed G129R, an antagonist of human PRL, to block the PRL/PRLR axis in both PTENwt and PTENmut orthotopic mouse models of uterine cancer. In comparison with control groups, treatment with G129R as monotherapy or in combination with paclitaxel resulted in a significant reduction of growth and progression of orthotopic uterine tumors. Results from protein profiling of uterine cancer cells and in vivo tumors revealed a set of new downstream targets for G129R. Our results showed that G129R induced sub-G0 population arrest, decreased nascent protein synthesis, and initiated FOXO3a/EIF-4EBP1–mediated cell death in both PTENwt and PTENmut uterine cancer cells. Collectively, our results show a unique pattern of PRLR_SF expression predominantly in uterine cancer. Moreover, FOXO3a and EIF-4EBP1 are important mediators of cell death following G129R treatment in uterine cancer models.